Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine.
D000284:Administration, Oral; D000619:Aminohydrolases / Q000037:antagonists & inhibitors; D000818:Animals; D002452:Cell Count; D003561:Cytarabine / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000378:metabolism; D003841:Deoxycytidine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D007939:Leukemia L1210 / Q000378:metabolism; D007951:Leukemia, Myeloid / Q000097:blood* / Q000188:drug therapy; D007962:Leukocytes; D051379:Mice; D014529:Uridine / Q000008:administration & dosage / Q000494:pharmacology*
D004273:DNA, Neoplasm; D003561:Cytarabine; D003841:Deoxycytidine; D000619:Aminohydrolases; D014529:Uridine